Here are the 10-K annual reports from Sutro Biopharma, Inc. (STRO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow STRO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STRO filings page.
Sutro Biopharma is a clinical-stage oncology company focused on next‑generation antibody-drug conjugates (ADCs) built on its proprietary cell-free protein synthesis platforms XpressCF® and XpressCF+®. Its lead wholly owned program, STRO‑004, targets tissue factor in multiple solid tumors and entered a Phase 1 trial in late 2025, with initial data expected in mid‑2026.
Preclinical assets include STRO‑006 (ITGβ6‑targeted ADC) and STRO‑227 (dual‑payload PTK7‑targeted ADC), with planned IND filings between 2026 and early 2027. The company highlights its ability to precisely place non‑natural amino acids to create homogeneous, high‑DAR ADCs and dual‑payload constructs, including immunostimulatory ADCs (iADCs) and dpADCs.
Sutro reports aggregate collaboration payments of about $1.016 billion through December 31, 2025, including a $90.0 million upfront from Astellas and a $140.0 million royalty monetization with Blackstone tied to Vaxcyte vaccines. Market value of non‑affiliate equity was approximately $60.0 million as of June 30, 2025, with 16,567,238 shares outstanding as of March 16, 2026.